Dr. Ulrich Rümenapp, Bayer AG - Qepler Summits And Conferences

Dr. Ulrich Rümenapp

Head of Launch Preparation and Coordination
Bayer AG
Berlin, Germany
We exist to help people thrive - Advancing health and nutrition is what we do best and care about most.

Dr. Rümenapp is based in Wuppertal, Germany and works within the Biological Development Organisation of Bayer AG, where he is responsible for the transfer of Bayer’s pipeline candidates (antibodies and antibody drug conjugates) to external manufacturing partners and regulatory submission and launch preparations.

Prior to working in development, Dr. Rümenapp was head of biotech projects in Product Supply Biotech at Bayer, where he was responsible for contract manufacturing partnerships in the field of biotechnological drug substances, drug products, and interdisciplinary project management with the goal to ensure market supply.

Before it was acquired by Bayer, Dr. Rümenapp held a similar position at Schering AG, and before that, he worked in the production & logistics department of Schering, where he was responsible for production aspects of in-andout-licensing deals, due diligences, and product acquisitions of small molecule products and biologics.

Dr. Rümenapp studied chemistry and holds a Ph.D. in biosciences. He has several years of experience in academic research in the field of signal transduction and as an assistant teacher in the field of general pharmacology.

Currently, Dr. Rümenapp’s area of expertise is the set-up and management of external relationships for the development and supply of bio-pharmaceutical products. He has more than 15 years of experience in the biopharmaceutical industry.

Related Sessions:

2nd Annual Highly Potent APIs
Summit 2020

Assess and reduce manufacturing and handling challenges for highly potent active pharmaceutical ingredients.
  • 19 Feb 2020
  • Prague, CZ
  • Pharma
Day 2: Thursday, 20 February 2020
CASE STUDY: Antibody-Drug Conjugates – antibodies meeting HPAPIs for specific and efficient bio-pharmaceutical drugs
  • ADCs - conjugation of antibodies with small molecule toxins
  • The manufacture of ADCs - challenges and solutions
  • Bayer’s ADC production concept using HPAPIs
View Details